RESUMO
The COVID-19 pandemic has led to the admission of a high number of patients to the ICU, generally due to severe respiratory failure. Since the appearance of the first cases of SARS-CoV-2 infection, at the end of 2019, in China, a huge number of treatment recommendations for this entity have been published, not always supported by sufficient scientific evidence or with methodological rigor necessary. Thanks to the efforts of different groups of researchers, we currently have the results of clinical trials, and other types of studies, of higher quality. We consider it necessary to create a document that includes recommendations that collect this evidence regarding the diagnosis and treatment of COVID-19, but also aspects that other guidelines have not considered and that we consider essential in the management of critical patients with COVID-19. For this, a drafting committee has been created, made up of members of the SEMICYUC Working Groups more directly related to different specific aspects of the management of these patients (AU)
La pandemia por COVID-19 ha provocado el ingreso de un elevado número de pacientes en UCI, generalmente por insuficiencia respiratoria severa. Desde la aparición de los primeros casos de infección por SARS-CoV-2, a finales de 2019, en China, se ha publicado una cantidad ingente de recomendaciones de tratamiento de esta entidad, no siempre respaldadas por evidencia científica suficiente ni con el rigor metodológico necesario. Gracias al esfuerzo de distintos grupos de investigadores, actualmente disponemos de resultados de ensayos clínicos, y otro tipo de estudios, de mayor calidad. Consideramos necesario realizar un documento que incluya recomendaciones que recojan estas evidencias en cuanto al diagnóstico y el tratamiento de COVID-19, pero también aspectos que otras guías no han contemplado y que consideramos fundamentales en el manejo del paciente crítico con COVID-19. Para ello se ha creado un comité redactor, conformado por miembros de los Grupos de Trabajo de SEMICYUC más directamente relacionados con diferentes aspectos específicos del manejo de estos pacientes (AU)
Assuntos
Humanos , Infecções por Coronavirus/terapia , Pneumonia Viral/terapia , Pandemias , Unidades de Terapia Intensiva , Protocolos Clínicos , Estado TerminalRESUMO
The COVID-19 pandemic has led to the admission of a high number of patients to the ICU, generally due to severe respiratory failure. Since the appearance of the first cases of SARS-CoV-2 infection, at the end of 2019, in China, a huge number of treatment recommendations for this entity have been published, not always supported by sufficient scientific evidence or with methodological rigor necessary. Thanks to the efforts of different groups of researchers, we currently have the results of clinical trials, and other types of studies, of higher quality. We consider it necessary to create a document that includes recommendations that collect this evidence regarding the diagnosis and treatment of COVID-19, but also aspects that other guidelines have not considered and that we consider essential in the management of critical patients with COVID-19. For this, a drafting committee has been created, made up of members of the SEMICYUC Working Groups more directly related to different specific aspects of the management of these patients.
Assuntos
COVID-19 , Estado Terminal/terapia , Humanos , Unidades de Terapia Intensiva , Pandemias , SARS-CoV-2RESUMO
The COVID-19 pandemic has led to the admission of a high number of patients to the ICU, generally due to severe respiratory failure. Since the appearance of the first cases of SARS-CoV-2 infection, at the end of 2019, in China, a huge number of treatment recommendations for this entity have been published, not always supported by sufficient scientific evidence or with methodological rigor necessary. Thanks to the efforts of different groups of researchers, we currently have the results of clinical trials, and other types of studies, of higher quality. We consider it necessary to create a document that includes recommendations that collect this evidence regarding the diagnosis and treatment of COVID-19, but also aspects that other guidelines have not considered and that we consider essential in the management of critical patients with COVID-19. For this, a drafting committee has been created, made up of members of the SEMICYUC Working Groups more directly related to different specific aspects of the management of these patients.
RESUMO
OBJECTIVE: To analyze the profile, incidence of life support therapy limitation (LSTL) and donation potential in neurocritical patients. STUDY DESIGN: A multicenter prospective study was carried out. SETTING: Nine hospitals authorized for organ harvesting for transplantation. PATIENTS: All patients consecutively admitted to the hospital with GCS < 8 during a 6-month period were followed-up until discharge or day 30 of hospital stay. STUDY VARIABLES: Demographic data, cause of coma, clinical status upon admission and outcome were analyzed. LSTL, brain death (BD) and organ donation incidence were recorded. RESULTS: A total of 549 patients were included, with a mean age of 59.0 ± 14.5 years. The cause of coma was cerebral hemorrhage in 27.0% of the cases.LSTL was applied in 176 patients (32.1%). In 78 cases LSTL consisted of avoiding ICU admission. Age, the presence of contraindications, and specific causes of coma were associated to LSTL. A total of 58.1% of the patients died (n=319). One-hundred and thirty-three developed BD (24.2%), and 56.4% of these became organ donors (n=75). The presence of edema and mid-line shift on the CT scan, and transplant coordinator evaluation were associated to BD. LSTL was associated to a no-BD outcome. Early LSTL (first 4 days) was applied in 9 patients under 80 years of age, with no medical contraindications for donation and a GCS ≤ 4 who finally died in asystole. CONCLUSIONS: LSTL is a frequent practice in neurocritical patients. In almost one-half of the cases, LSTL consisted of avoiding admission to the ICU, and on several occasions the donation potential was not evaluated by the transplant coordinator.
Assuntos
Morte Encefálica , Coma/terapia , Cuidados Críticos , Eutanásia Passiva , Cuidados para Prolongar a Vida , Recusa em Tratar/estatística & dados numéricos , Doadores de Tecidos/provisão & distribuição , Coleta de Tecidos e Órgãos , Obtenção de Tecidos e Órgãos/organização & administração , Adulto , Idoso , Idoso de 80 Anos ou mais , Dano Encefálico Crônico/etiologia , Morte Encefálica/diagnóstico , Coma/etiologia , Coma/mortalidade , Feminino , Humanos , Unidades de Terapia Intensiva/estatística & dados numéricos , Cuidados para Prolongar a Vida/estatística & dados numéricos , Masculino , Futilidade Médica , Pessoa de Meia-Idade , Estudos Prospectivos , Espanha , Assistência Terminal/estatística & dados numéricos , Coleta de Tecidos e Órgãos/estatística & dados numéricos , Obtenção de Tecidos e Órgãos/métodosRESUMO
Objetivo. Analizar el perfil, la incidencia de limitaciónde tratamiento de soporte vital (LTSV) y la potencialidad de donación de órganos enpacientes neurocríticos. Diseño Multicéntrico prospectivo. Ámbito Nueve centros autorizados para extracción de órganos para trasplante...
Assuntos
Doação Dirigida de Tecido , Morte Encefálica/diagnósticoRESUMO
We are used to comparisons of activity using donation or transplantation population (pmp) rates between regions or countries, without a further evaluation of the process. But crude pmp rates do not clearly reflect real transplantation capacity, because organ procurement does not finish with the donation step; it is also necessary to know the utilization of the obtained organs. The objective of this study was to present methods and indicators deemed necessary to evaluate the effectiveness of the process. We have proposed the use of simple definitions and indicators to more accurately measure and compare the effectiveness of the total organ procurement process. To illustrate the use and performance of these indicators, we have presented the donation and transplantation activity in Catalonia from 2002 to 2007.
Assuntos
Obtenção de Tecidos e Órgãos/estatística & dados numéricos , Humanos , Reprodutibilidade dos Testes , Doadores de Tecidos/estatística & dados numéricosRESUMO
La pandemia de gripe A H1N1 supone un reto para el sistema sanitario, en general, y para las unidades de cuidados intensivos (UCI), en particular, por lo que tendrá sin duda repercusiones sobre el proceso de donación de órganos y tejidos. Por una parte, en un escenario posible de escasez de camas de la UCI y de dificultades para mantener la actividad quirúrgica a un ritmo normal, será necesario realizar un esfuerzo para crear las condiciones que aseguren el mantenimiento de la actividad trasplantadora, que no debe considerarse una actividad electiva. El otro problema relacionado con el impacto de la pandemia sobre la donación de órganos es la posibilidad de que un donante con gripe pueda transmitir la enfermedad vírica a los receptores. El presente trabajo tiene como objetivo clarificar esta cuestión, y revisar los datos existentes sobre la posibilidad de transmisión del virus de la gripe con los órganos o los tejidos trasplantados, las recomendaciones que se han dado en otros países y las que ha elaborado un grupo de trabajo ad hoc, constituido por representantes de la Organización Nacional de Trasplantes, del Ministerio de Sanidad y Política Social, de las coordinaciones autonómicas de trasplantes y de diversas sociedades científicas, incluida la Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (AU)
The pandemic strain of H1N1 supposes a challenge to the health care system in general and for Intensive Care Units (ICU) in particular. Therefore, it will undoubtedly have repercussions on the organ and tissue donation process. In a possible scenario of bed shortage in the ICU and difficulties in maintaining the surgical activity at a normal pace, a significant effort must be made to assure the maintenance of normal transplant activity, which should not be considered as an elective surgical procedure. Another problem related with the impact of the pandemic on the organ donation process is the possibility that a donor with influenza virus could transmit the disease to recipients. This work aims to clarify this issue, reviewing existing data on the potential transmission of influenza viruses with transplanted organs or tissue, the recommendations published in other countries and those developed in Spain by an ad hoc work group that is made up by representatives from the National Transplant Organization, the Ministry of Health and Social Policy, Regional Offices of Transplant Coordination, and various scientific societies, including SEMICYUC (AU)
Assuntos
Humanos , Surtos de Doenças , Vírus da Influenza A Subtipo H1N1/patogenicidade , Doadores de Tecidos , Influenza Humana/epidemiologia , Obtenção de Tecidos e Órgãos/normas , Algoritmos , Argentina , Austrália , Influenza Humana/diagnóstico , Influenza Humana/transmissão , Unidades de Terapia Intensiva , Nova Zelândia , Transplante de Órgãos/efeitos adversos , Espanha , Reino UnidoRESUMO
The pandemic strain of H1N1 supposes a challenge to the health care system in general and for Intensive Care Units (ICU) in particular. Therefore, it will undoubtedly have repercussions on the organ and tissue donation process. In a possible scenario of bed shortage in the ICU and difficulties in maintaining the surgical activity at a normal pace, a significant effort must be made to assure the maintenance of normal transplant activity, which should not be considered as an elective surgical procedure. Another problem related with the impact of the pandemic on the organ donation process is the possibility that a donor with influenza virus could transmit the disease to recipients. This work aims to clarify this issue, reviewing existing data on the potential transmission of influenza viruses with transplanted organs or tissue, the recommendations published in other countries and those developed in Spain by an ad hoc work group that is made up by representatives from the National Transplant Organization, the Ministry of Health and Social Policy, Regional Offices of Transplant Coordination, and various scientific societies, including SEMICYUC.